Ride2Abide,,2019-06-06 15:33:00,92.133,VKTX From Allison GatlinIBDAGatlinICPT MDGL VKTX AGN and GILD are down today after the FDA said some of the endpoints in clinical studies might not be sufficient for approval of NASH drugs for patients with compensated cirrhosis biotech stocks investing1207 PM 6 Jun 2019 Good thing VKTX hasnt started their P2b trial just adjust their Endpoints and all good
bioguru33,,2019-06-06 14:24:00,90.8,MDGL well done mgmt take a bow
BDRCap,True,2019-06-06 11:32:00,92.84,MDGL Why
